TYRA — Tyra Biosciences, Inc. stock price, charts and financials

QT77Tyra Biosciences, Inc.

Tyra Biosciences, Inc. (NASDAQ: TYRA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
25.73
+1.30+5.32%
OverviewShort InterestFilings
TYRAQT77Tyra Biosciences, Inc.·NASDAQ
25.73+5.32%
News
Up 5.3% — Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market buyHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
RAPP-3.58%$40.45GHRS-1.60%$28.26MESO+1.75%$15.13ZYME-3.31%$26.57AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83GPCR-0.28%$35.00
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand59.66MPerf Week16.80%
Market Cap1.54BForward P/E-EPS next Y-2.90Insider Trans20.27%Shs Float44.33MPerf Month-4.03%
Enterprise Value1.47BPEG0.39EPS next Q-0.67Inst Own-Short Float21.30%Perf Quarter-9.15%
Income-134.32MP/S0.00EPS this Y-Inst Trans-Short Ratio12.33Perf Half Y-32.61%
Sales0.00P/B4.80EPS next Y-8.46%ROA-38.75%Short Interest9.44MPerf YTD-2.13%
Book/sh-P/C-EPS next 5Y-ROE-46.39%52W High40.65 -36.70%Perf Year111.77%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-44.78%52W Low12.27 109.70%Perf 3Y74.20%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility7.69% 6.87%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-58.94%Oper. Margin0.00%ATR (14)2.09Perf 10Y-
Dividend Ex-Date-Quick Ratio14.91Sales Y/Y TTM-Profit Margin0.00%RSI (14)50.01Recom2.00
Dividend Gr. 3/5Y-Current Ratio14.91EPS Q/Q-46.81%SMA202.02%Beta0.56Target Price50.67
Payout0.00%Debt/Eq0.02Sales Q/Q-SMA50-7.27%Rel Volume2.37Prev Close24.43
Employees87LT Debt/Eq0.02EarningsNov 04SMA200-15.60%Avg Volume873.96KPrice25.73
IPO DateSep 15, 2021Option/ShortYes / YesEPS/Sales Surpr.-6.17% -Net Debt/EBITDA0.46Volume2,069,682Change5.32%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-08-26ReiteratedPiper SandlerOverweight$42 → $56
Aug-05-26ReiteratedJefferiesBuy$44 → $42
Apr-14-26InitiatedGuggenheimBuy$54
Feb-17-26ReiteratedHC Wainwright & Co.Buy$30 → $45
Feb-13-26ReiteratedWedbushOutperform$37 → $53
Feb-03-26ReiteratedOppenheimerOutperform$36 → $50
Jan-27-26InitiatedBarclaysOverweight$59
Jan-23-26ReiteratedPiper SandlerOverweight$42
Dec-16-25ReiteratedWedbushOutperform$37
Sep-10-25ReiteratedOppenheimerOutperform$30 → $36
Latest News· Times ET
Sep-16-26
Sep-16-2604:07PM
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?Yahoo
Sep-15-26
Sep-15-2601:32PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAglobenewswire.com
Sep-14-26
Sep-14-2602:45AM
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrantsprnewswire.com
Sep-10-26
Sep-10-2603:20PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAprnewswire.com
06:47AM
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC TranscriptSeekingAlpha
Sep-09-26
Sep-09-2608:39AM
Why Is Tyra Biosciences Stock Sinking Wednesday?benzinga.com
06:53AM
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Resultsinvestors.com
06:44AM
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impressbarrons.com
03:00AM
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinibprnewswire.com
Sep-08-26
Sep-08-2612:05PM
Tyra Biosciences to Present at the Cantor Global Healthcare Conferenceprnewswire.com
Sep-06-26
Sep-06-2607:14AM
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readoutsseekingalpha.com
Sep-04-26
Sep-04-2603:00PM
Which stocks are experiencing notable movement on Friday?ChartMill
04:00AM
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026prnewswire.com
Aug-30-26
Aug-30-2610:15PM
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of “Moderate Buy” by Analystsdefenseworld.net
Aug-26-26
Aug-26-2611:35PM
Algert Global LLC Buys 51,110 Shares of Tyra Biosciences, Inc. $TYRAdefenseworld.net
Company

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000————
Cost of Goods Sold Incl. D&A
000————
Gross Profit
000————
Selling, General and Administrative Excl. Other302417————
Research and Development1038063————
Other Operating Expense
000————
Operating Income-133-104-80————
Interest Expense
000————
Unusual Expense
———————
Non-Operating Income (Expense)131811————
Net Income Before Taxes-120-86-69————
Income Taxes
000————
Consolidated Net Income-120-86-69————
Net Income From Continuing Operations-120-86-69————
Net Income-120-86-69————
EPS (Recurring)-2.01-1.51-1.62————
EPS (Basic, Before Extraordinaries)-2.01-1.51-1.62————
EPS (Diluted)-2.01-1.51-1.62————
EBITDA-119-86-69————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding605743————
Market Capitalization1,577792596————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$44.04$34.45$24.85$15.26$5.67● Close Price0.00M2.28M4.57M6.85M9.14MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:Sep 15 '26Buy0.009,078,5299,07911,616,986Sep 17
Verjee RehanDirectorSep 09 '26Buy20.5897220,000972Sep 11
KAPLAN GILLADirectorMar 26 '26Option Exercise2.25106,344239,27481,403Mar 27
KAPLAN GILLADirectorMar 25 '26Option Exercise2.2514,29532,16442,526Mar 27
KAPLAN GILLADirectorMar 25 '26Sale36.9714,295528,50628,231Mar 27
Bensen DanielChief Discovery OfficerFeb 12 '26Sale32.878,000262,965146,981Feb 13
Bensen DanielChief Discovery OfficerJan 12 '26Sale28.528,000228,185154,981Jan 20
MORE ROBERT JDirectorDec 19 '25Sale25.0010,000250,0003,823,425Dec 19
Bensen DanielChief Discovery OfficerDec 12 '25Sale22.648,000181,159162,981Dec 16
MORE ROBERT JDirectorNov 21 '25Sale20.25246,8715,000,0263,833,425Nov 25
Bensen DanielChief Operating OfficerNov 19 '25Sale16.3249,956815,297170,981Nov 19
Bensen DanielChief Operating OfficerNov 18 '25Sale16.0775,6331,215,627220,937Nov 19
Bensen DanielChief Operating OfficerNov 17 '25Sale16.1820,072324,798296,570Nov 17
Bensen DanielChief Operating OfficerNov 14 '25Sale16.02110,2281,765,489316,642Nov 17
Bensen DanielChief Operating OfficerNov 13 '25Sale16.001,11117,780426,870Nov 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.